fashion -WSS

fashion

author：hotspot 2025-09-30 20:17:46 - browse：36967

Insitro CEO and founder Daphne Koller Neilson Barnard/Getty Images for The New York Times

SAN FRANCISCO — It took only a single, one-hour meeting in a Starbucks to convince venture capitalist Robert Nelsen that he was going to invest in the company being built by machine-learning whiz Daphne Koller. “She’s just an amazing force of nature,” said Nelsen, who invests for ARCH Venture Partners.

Koller’s company, Insitro, in a matter of months raised over $100 million from big-name investors including ARCH, Foresite Capital, Andreessen Horowitz, and the firm that manages Jeff Bezos’ personal VC investments. (Koller refers to Bezos by his first name.) Now, it’s time for the next step. On Tuesday, the giant drug maker Gilead Sciences said it would pay Insitro $15 million — and up to $1 billion more down the line if it meets certain goals — for help in developing drugs to treat a common liver disease. It is the South San Francisco-based company’s first deal with a drug maker, and offers a test of whether artificial intelligence can remake drug development.

The very nature of the financials emphasize the exciting but risky reality: The technology has great promise, but nothing is guaranteed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Fertility clinic egg and embryo storage is a disaster

WSS

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

STAT reporters are Pulitzer Prize finalists for investigative reporting

Gene therapy’s promise and the high cost of hope

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Free medical tuition alone isn't enough to close gaps in primary care

Obesity drug from Roche shows promise in early study

explore

fashion

hotspot

Medical records are filled with copy

The White House hikes tariffs on plastic syringes made in China

Heart attack and stroke risk calculators need revising

Coloradans with cystic fibrosis could lose access to Trikafta

Psychedelics group wrestles with new pharma identity

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Malaria cases in Florida and Texas: Here’s what you need to know

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

As demand for Covid shots wanes, Moderna seeks its next success

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

knowledge

Abbott's new stent may help patients with peripheral artery disease

How neuroscience research could help beat back brain cancer

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

Life sciences investors close nearly $6 billion in new funds

After Sarepta trial failure, Duchenne families brace for more debate

Brain injuries and the importance of a second opinion

focus

knowledge

hotspot

entertainment